Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CoreWeave
CRWV
5
Palantir
PLTR
(FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 125.21%1.1B | 68.08%317.44M | -0.37%489.31M | -29.65%188.86M | -74.13%491.13M | -75.51%268.45M | 12.49%1.9B | 42.51%1.1B | -7.85%1.69B | -11.31%769.3M |
Operating income | 125.21%1.1B | 68.08%317.44M | -0.37%489.31M | -29.65%188.86M | -74.13%491.13M | -75.51%268.45M | 12.49%1.9B | 42.51%1.1B | -7.85%1.69B | -11.31%769.3M |
Cost of sales | -128.12%-591.88M | -46.73%-174.72M | 18.43%-259.46M | 18.87%-119.08M | 72.80%-318.07M | 78.24%-146.77M | -9.01%-1.17B | -36.13%-674.43M | -0.81%-1.07B | 2.59%-495.44M |
Operating expenses | -128.12%-591.88M | -46.73%-174.72M | 18.43%-259.46M | 18.87%-119.08M | 72.80%-318.07M | 78.24%-146.77M | -9.01%-1.17B | -36.13%-674.43M | -0.81%-1.07B | 2.59%-495.44M |
Gross profit | 121.93%510.12M | 104.53%142.72M | 32.82%229.86M | -42.65%69.78M | -76.27%173.06M | -71.16%121.67M | 18.56%729.35M | 54.07%421.93M | -19.86%615.19M | -23.67%273.85M |
Selling expenses | -191.42%-76.01M | -225.09%-22.72M | 19.62%-26.08M | 77.05%-6.99M | 82.07%-32.45M | 75.55%-30.45M | 7.21%-180.98M | -39.69%-124.54M | -19.91%-195.05M | -46.89%-89.16M |
Administrative expenses | -142.35%-140.29M | -42.97%-40.95M | 34.74%-57.89M | 35.49%-28.64M | 60.22%-88.69M | 61.98%-44.4M | -4.14%-222.96M | -9.36%-116.77M | 11.64%-214.09M | -11.45%-106.78M |
Research and development expenses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -8.06%-84.96M | -0.07%-165.57M | 4.41%-78.63M |
Profit from asset sales | -97.02%581K | ---- | 5,433.06%19.52M | 9,161.47%19.75M | 99.74%-366K | ---218K | ---140.18M | ---- | ---- | ---- |
Revaluation surplus | 97.74%-878K | 116.11%2.89M | -213.73%-38.91M | 10.70%-17.94M | 91.41%-12.4M | ---20.09M | ---144.44M | ---- | ---- | ---- |
-Changes in the fair value of financial assets | 97.74%-878K | 116.11%2.89M | -213.73%-38.91M | 10.70%-17.94M | 91.41%-12.4M | ---20.09M | ---144.44M | ---- | ---- | ---- |
Impairment and provision | -34.11%-7.41M | 90.50%-530K | -129.50%-5.53M | -126.06%-5.58M | 110.73%18.74M | --21.42M | ---174.57M | ---- | ---- | ---- |
-Impairment of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---6.47M | ---- | ---- | ---- |
-Impairment of property, machinery and equipment | ---- | ---- | ---- | ---- | ---- | ---- | ---11.76M | ---- | ---- | ---- |
-Other impairment is provision | -34.11%-7.41M | 90.50%-530K | -129.50%-5.53M | -126.06%-5.58M | 111.98%18.74M | --21.42M | ---156.34M | ---- | ---- | ---- |
Operating interest expense | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---30.46M | ---53.04M | ---- |
Special items of operating profit | -1,077.55%-25.74M | 17.00%-1.98M | 3,756.94%2.63M | 89.29%-2.39M | 99.90%-72K | -135.01%-22.3M | -198.02%-73.65M | 171.73%63.68M | 299.25%75.14M | 123.89%23.44M |
Operating profit | 110.66%260.38M | 183.68%79.43M | 113.80%123.61M | 9.22%28M | 127.87%57.81M | -80.11%25.64M | -431.52%-207.43M | 467.12%128.88M | -71.04%62.57M | -82.58%22.73M |
Financing cost | -30.89%-11.74M | -13.64%-5.19M | 27.49%-8.97M | 40.98%-4.57M | 78.60%-12.37M | ---7.74M | ---57.8M | ---- | ---- | 2.13%-24.57M |
Share of profits of associates | 83.22%-171K | -135.92%-74K | -1,979.59%-1.02M | 143.10%206K | 99.35%-49K | 75.69%-478K | -205.43%-7.53M | 54.93%-1.97M | 31.25%-2.47M | -1,987.08%-4.36M |
Share of profit from joint venture company | ---- | ---- | 25.59%-858K | 33.77%-402K | -65.19%-1.15M | -797.70%-607K | -752.34%-698K | 1.16%87K | -6.14%107K | -4.44%86K |
Special items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -292.21%-118.36M | 1,167.13%82.8M | 524.11%61.58M |
Earning before tax | 120.35%248.47M | 219.16%74.17M | 154.85%112.76M | 38.20%23.24M | 116.18%44.25M | 94.57%16.82M | -291.22%-273.46M | -84.42%8.64M | -8.81%143.01M | -38.87%55.46M |
Tax | -145.33%-56.13M | -540.05%-19.75M | -332.84%-22.88M | 72.61%-3.09M | 118.85%9.83M | -55.76%-11.27M | -242.67%-52.14M | -192.64%-7.23M | 30.66%-15.22M | 84.02%-2.47M |
After-tax profit from continuing operations | 114.00%192.34M | 170.02%54.42M | 66.22%89.88M | 263.30%20.15M | 116.61%54.07M | 293.96%5.55M | -354.78%-325.59M | -97.34%1.41M | -5.25%127.79M | -29.59%52.99M |
Earning after tax | 114.00%192.34M | 170.02%54.42M | 66.22%89.88M | 263.30%20.15M | 116.61%54.07M | 293.96%5.55M | -354.78%-325.59M | -97.34%1.41M | -5.25%127.79M | -29.59%52.99M |
Minority profit | 91.80%-112K | 85.36%-112K | 38.30%-1.37M | -342.86%-765K | -293.95%-2.21M | 107.11%315K | 70.12%-562K | -191.12%-4.43M | -182.43%-1.88M | -204.81%-1.52M |
Profit attributable to shareholders | 110.91%192.45M | 160.68%54.53M | 62.11%91.25M | 299.79%20.92M | 117.32%56.29M | -10.35%5.23M | -350.65%-325.03M | -89.29%5.84M | -4.33%129.68M | -28.05%54.51M |
Basic earnings per share | 111.30%0.2561 | 160.79%0.0725 | 62.03%0.1212 | 297.14%0.0278 | 117.31%0.0748 | -12.50%0.007 | -363.41%-0.432 | -88.41%0.008 | -5.20%0.164 | -28.87%0.069 |
Diluted earnings per share | 110.89%0.2556 | 160.07%0.0723 | 62.03%0.1212 | 297.14%0.0278 | 117.31%0.0748 | -12.50%0.007 | -370.00%-0.432 | -88.06%0.008 | -6.43%0.16 | -30.93%0.067 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
Auditor | -- | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Ernst & Young | -- | Ernst & Young | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.